



Annual Report 2021

of the certified Gynaecology Cancer Centres

Audit year 2020 / Indicator year 2019

Table of Contents

Introduction	3
General information.....	3
Status of the certification system for Gynaecology Cancer Centres 2020.....	5
Clinical sites taken into account.....	6
Tumour documentation systems in the Centres' clinical sites.....	7
Analysis of basic data.....	8
Analysis of indicators.....	12
Indicator No. 1: Presentation tumour board.....	12
Indicator No. 2: Psycho-oncological counselling (session \geq 25 min).....	13
Indicator No. 3: Counselling social services	14
Indicator No. 4: Study participation.....	15
Indicator No. 5: Total case number	16
Indicator No. 6: Primary cases	17
Indicator No. 7: Surgical cases	18
Indicator No. 8: Offering of genetic testing (GL ovary QI 2).....	19
Indicator No. 9: Surgical staging early ovarian cancer (GL ovary QI 1).....	20
Indicator No. 10: Macroscopic complete resection advanced ovarian cancer (GL ovary QI 3).....	21
Indicator No. 11: Surgery advanced ovarian cancer (GL ovary QI 4).....	22
Indicator No. 12: Post-surgical chemotherapy advanced ovarian cancer (GL ovary QI 5).....	23
Indicator No. 13: First-line chemotherapy of advanced ovarian cancer (GL ovary QI 8).....	24
Indicator No. 14: Presentation at the tumour board (LL cervix QI 1).....	25
Indicator No. 15: Details in the pathology report in the case of initial diagnosis and tumour resection (GL cervix QI 2).....	26
Indicator No. 16: Details in the pathology report in the case of lymphonodectomy (GL cervix QI 3).....	27
Indicator No. 17: Cytological/histological lymph node staging (GL cervix QI 4).....	28
Indicator No. 18: Brachytherapy as a component of primary radio(chemo) therapy.....	29
Indicator No. 19: Details in pathology report in the case of initial diagnosis and tumour resection (GL vulva QI 1).....	30
Indicator No. 20: Details in pathology report in the case of lymphonodectomy (GL vulva QI 2).....	31
Indicator No. 21: Conduct inguino femoral staging (GL vulva QI 6).....	32
Indicator No. 22: Sentinel lymph nodes biopsy (GL vulva QI 7)	33
Indicator No. 23: Systematic lymphadenectomy (LNE) for type-I-endometrial carcinoma (GL endo. QI 1)	34
Indicator No. 24: Adjuvant chemotherapy for type-I-endometrial carcinoma (GL endo QI 2).....	35
Impressum	36

General information

Indicator No. 1:	Presentation tumour board
Indicator No. 2:	Psycho-oncological counselling (session ≥ 25 min)
Indicator No. 3:	Counselling social services
Indicator No. 4:	Study participation
Indicator No. 5:	Total case number with a genital malignoma
Indicator No. 6:	Primary cases with a genital malignoma
Indicator No. 7:	Surgical cases with a genital malignoma
Indicator No. 8:	Surgical staging early ovary carcinoma (GL ovary QI 1)
Indicator No. 9:	Macroscopic complete resection advanced ovary carcinoma (GL ovary QI 3)
Indicator No. 10:	Surgery advanced ovary carcinoma (GL ovary QI 4)
Indicator No. 11:	Post-surgical chemotherapy advanced ovary carcinoma (GL ovary QI 5)
Indicator No. 12:	No adjuvant chemotherapy of early ovary carcinoma (LL ovary QI 6)
Indicator No. 13:	Platin-containing chemotherapy early ovary carcinoma (GL ovary QI 7)
Indicator No. 14:	First-line chemotherapy of advanced ovary carcinoma (GL ovary QI 8)

Quality indicators of the guidelines (GL QI):

In the table of contents and in the respective headings the indicators, which correspond to the quality indicators of the evidence-based guidelines are specifically identified. The quality indicators identified in this way are based on the strong recommendations of the guidelines and were derived from the guidelines groups in the context of the guideline programme oncology. Further information: www.leitlinienprogramm-onkologie.de

	Definition of indicator	All clinical sites 2014	
		Median	Range
Numerator	All surgically treated primary cases presented in the tumour conference	151*	46 - 801
Population	Surgically treated primary cases (for definition of a primary case see 5.2.1)	152*	46 - 806
Rate	Target ≥ 95%	100%	93.75% - 100%

Basic data indicator:

The definitions of numerator, population (=denominator) and target value are taken from the Data Sheet.

The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators.

The values for the numerators, populations and rates of all Centres are given under range.

The Total Patients column shows the total of all patients treated according to the key figure and the corresponding quota.





Diagram:


The x-axis indicates the number of Centres, the y-axis gives the values in percent or number (e.g. primary cases). The target value is depicted as a horizontal green line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.

General information



Cohort development:

The cohort development in the years 2015, 2016, 2017, 2018 and 2019 is presented in a box plot diagram.



Box plot:

A box plot consists of a **box with median, whiskers** and **outliers**. 50 percent of the Centres are within the box. The median divides the entire available cohort into two halves with an equal number of Centres. The whiskers and the box encompass a 90th percentile area/range. The extreme values are depicted here as dots.

Maximalwert = Maximum value
Antenne = Antenna
Minimalwert = Minimum value

Status of the certification system for Gynaecology Cancer Centres 2020

	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016	31.12.2015
Ongoing procedures	8	12	4	10	6	8
Certified Centres	164	155	143	134	133	123
Certified clinical sites	165	156	145	136	135	125
Gynaecology Cancer Centres with 1 clinical site	163	154	141	132	131	121
2 clinical sites	1	1	2	2	2	2
3 clinical sites	0	0	0	0	0	0
4 clinical sites	0	0	0	0	0	0

Clinical sites taken into account

	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016	31.12.2015
Clinical sites included in the Annual Report	162	149	139	128	125	112
equivalent to	98.8%	95.5%	95.9%	94.1%	92.6%	89.6%
Primary cases total*	14,986	13,762	12,937	12,087	11,587	10,412
Primary cases per clinical site (mean)*	92	92	93	94	93	93
Primary cases per clinical site (median)*	78	78	77	76	79	79


*The figures are based on the clinical sites listed in the Annual Report.

This annual report looks at the gynaecological cancer centres certified in the certification system of the German Cancer Society. The basis for the diagrams in the annual report is the data sheet.

The annual report includes 162 of the 165 certified centre locations. Excluded are 3 sites that were certified for the first time in 2020 (data mapping complete calendar year not mandatory for first-time certifications). A total of 15,206 primary cases with genital malignancy were treated at all 165 sites. An up-to-date overview of all certified sites is shown at www.oncomap.de.

The indicators published here refer to the key indicator year 2019. They represent the assessment basis for the audits carried out in 2020.

Tumour documentation systems in the Centres' clinical sites




Andere = other
 Tumorzentrum = Tumour centre
 Tumorregister = Tumour registry
 Entwicklung = Development

Legend:	
Other	System used in ≤ 3 clinical sites

The information on the tumour documentation system was taken from the data sheet (Basic Data Sheet). It is not possible to select more than one system. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumor documentation system.

Basic data – total case number (primary and non-primary cases)



	Total case number	Primary cases	Non-primary cases
Ovarian cancer	6.783 (32.36%)	4.055 (27.06%)	2.728 (45.63%)
Borderline ovary	1.017 (4.85%)	952 (6.35%)	65 (1.09%)
Cervical carcinoma	3.511 (16.75%)	2.636 (17.59%)	875 (14.64%)
Endometrial carcinoma	5.967 (28.46%)	4.798 (32.02%)	1.169 (19.56%)
Vulvar cancer	2.368 (11.30%)	1.637 (10.92%)	731 (12.23%)
Vaginal carcinoma	303 (1.45%)	214 (1.43%)	89 (1.49%)
Others*	1.015 (4.84%)	694 (4.63%)	321 (5.37%)
Total case number	20,964 (100%)	14,986 (100%)	5,978 (100%)


	Incidence ¹ Germany	Primary cases 2019 ²	Share 2020	Primary Cases Germany 2018	Share 2018
Ovarian cancer	7,292	3,798	52.08%	3,698	50.32%
Borderline ovary	-	884	-	814	-
Cervical carcinoma	4,341	2,479	57.10%	2,234	51.00%
Endometrial carcinoma	10,496	4,487	42.75%	4,203	39.66%
Vulvar cancer	3,301	1,579	47.83%	1,506	45.19%
Vaginal carcinoma	515	202	39.22%	212	46.29%
Others*	944	671	71.08%	576	67.76%

* Others (for instance sarcomas, chorion carcinomas, etc.)

¹ Centre for cancer register data in the Robert Koch-Institute, incidence 2017.

² including primary cases not yet part of the annual report (Germany only) database query www.krebsdaten.de/abfrage 18.05.2021

Basic data – primary and non-primary cases





	Primary cases		
	Total	operated	not operated
		absolute (in %)	absolute (in %)
Ovarian cancer	4,055 (100%)	3,544 (87.40%)	511 (12.60%)
Borderline ovary	952 (100%)	947 (99.47%)	5 (0.53%)
Cervical carcinoma	2,636 (100%)	2,018 (76.56%)	618 (23.44%)
Endometrial carcinoma	4,798 (100%)	4,455 (92.85%)	343 (7.15%)
Vulvar cancer	1,637 (100%)	1,453 (88.76%)	184 (11.24%)
Vaginal carcinoma	214 (100%)	123 (57.48%)	91 (42.52%)
Others*	694 (100%)	619 (89.19%)	75 (10.81%)
Total	14,986	13,159	1,827

	Non-primary cases		
	Total	operated	not operated
		absolute (in %)	absolute (in %)
Ovarian cancer	2,728 (100%)	560 (20.53%)	2,168 (79.47%)
Borderline ovary	65 (100%)	50 (76.92%)	15 (23.08%)
Cervical carcinoma	875 (100%)	222 (25.37%)	653 (74.63%)
Endometrial carcinoma	1,169 (100%)	344 (29.43%)	825 (70.57%)
Vulvar cancer	731 (100%)	457 (62.52%)	274 (37.48%)
Vaginal carcinoma	89 (100%)	36 (40.45%)	53 (59.55%)
Others*	321 (100%)	130 (40.50%)	191 (59.50%)
Total	5,978	1,799	4,179

* Others (for instance sarcomas, chorion carcinomas, etc.)

Surgical cases with a genital malignoma




¹ (Pat. with recurrence/ sec. distant metastasis)

	2015	2016	2017	2018	2019
Max	223.00	310.00	342.00	328.00	371.00
95. percentile	162.60	157.30	149.00	171.60	151.95
75. percentile	98.00	104.25	97.00	93.00	92.00
Median	71.00	68.00	71.00	70.00	67.00
25. percentile	58.00	58.00	57.00	56.00	54.25
5. percentile	47.20	44.35	44.00	41.40	40.00
Min	32.00	40.00	36.00	30.00	33.00


	2015	2016	2017	2018	2019
Max	69.00	69.00	92.00	89.00	92.00
95. percentile	35.40	30.00	30.20	32.60	28.95
75. percentile	14.00	17.00	13.00	13.00	12.00
Median	10.00	9.00	9.00	8.00	8.00
25. percentile	6.00	5.00	5.00	5.00	5.00
5. percentile	2.00	1.35	2.00	2.00	2.00
Min	0.00	0.00	0.00	1.00	0.00

Basic data - Primary cases ovary and cervix


Primärfälle operiert + Primärfälle nicht operiert



Primärfälle operiert + Primärfälle nicht operiert




1. Presentation tumour board



162 Clinical sites

Sollvorgabe = target value

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients with a genital malignoma who were presented at the tumour conference	95.5*	64 - 722	20,266
Denominator	Total case number (= indicator 5)	97*	68 - 722	20,964
Rate	Target value ≥ 80%	98.73%	80.38% - 100%	96.67%**



	2015	2016	2017	2018	2019
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	99.38%	99.64%	100%	100%	100%
Median	97.56%	97.98%	97.93%	98.17%	98.73%
25 th percentile	93.53%	96.09%	94.87%	95.35%	96.44%
5 th percentile	87.90%	87.91%	85.79%	87.36%	86.64%
Min	81.25%	81.07%	80.00%	72.04%	80.38%


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
162	100.00%	162	100.00%

Comments:
While 1 centre failed to meet the target in previous indicator year, all centres now meet the target of 80%. 60 centres succeeded in presenting all cases at the tumour board.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
** Percentage of the total number of patients treated in centres according to the indicator.




2. Psycho-oncological counselling (session ≥ 25 min)



162 Clinical sites

Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients (= cases, definition 1.2.1), who received, in an outpatient or inpatient setting, psycho-oncological counselling (session ≥ 25 min.)	57*	11 - 336	10,620
Denominator	Total case number (= indicator 5)	97*	68 - 722	20,964
Rate	Mandatory statement of reasons*** < 15% and >95%	51.49%	8.15% - 94.74%	50.66%**



	2015	2016	2017	2018	2019
Max	100%	100%	100%	95.00%	94.74%
95 th percentile	91.50%	87.27%	86.35%	83.98%	86.35%
75 th percentile	70.41%	71.46%	70.18%	69.51%	69.36%
Median	52.20%	51.72%	50.63%	51.81%	51.49%
25 th percentile	35.97%	36.05%	36.16%	35.05%	35.29%
5 th percentile	16.40%	17.69%	20.77%	19.05%	20.27%
Min	1.74%	10.11%	12.66%	10.42%	8.15%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	160	98.77%

Comments:

Psycho-oncological care has been very well established in the centres for years. Only 2 centres were below a quota of 15% and had to submit justifications for the audit. In both centres, the reason was fluctuations or bottlenecks among the responsible staff. Accordingly, the centres announced in the audits that they would increase staff or intensify screening. In this context, one of the centres referred to the additional outpatient care offered by the cancer counselling centres.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.




3. Counselling social services



Begründungspflicht = mandatory statement of reasons

162 Clinical sites

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients (= cases, definition 1.2.2), who received counselling by the social services in an inpatient or outpatient setting	66*	15 - 329	12,894
Denominator	Total case number (= indicator 5)	97*	68 - 722	20,964
Rate	Mandatory statement of reasons*** < 30%	65.91%	11.96% - 93.83%	61.51%**



	2015	2016	2017	2018	2019
Max	100%	100%	96.77%	96.04%	93.83%
95 th percentile	90.21%	88.58%	89.23%	88.51%	87.22%
75 th percentile	77.36%	75.55%	76.92%	75.53%	76.22%
Median	65.95%	66.00%	66.83%	65.43%	65.91%
25 th percentile	51.12%	52.36%	54.06%	51.61%	52.21%
5 th percentile	31.83%	29.14%	32.00%	31.69%	33.13%
Min	14.29%	11.56%	14.05%	12.62%	11.96%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	158	97.53%

Comments:
Social service counselling has also shown itself to be stable and very well implemented for years. Of the 4 centres requiring justification with a counselling rate below 30%, 3 were located in German-speaking countries where different responsibilities and entitlements to benefits apply. In the remaining centre, post-inpatient outpatient consultations were not documented in the HIS, which is to be remedied in the future.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.


*** If value is outside the plausibility corridor, centres have to give an explanation.



4. Study participation



	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients of the Gynaecology Centre included in a study with an ethical vote	7*	0 - 675	3,619
Denominator	Primary cases with a genital carcinoma (= indicator 6)	78*	48 - 413	14,986
Rate	Target value ≥ 5%	8.60%	0.00% - 300.00%	24.15%**



	2015	2016	2017	2018	2019
Max	146.19%	94.76%	77.03%	131.05%	300.00%
95 th percentile	45.41%	53.69%	45.66%	59.97%	54.16%
75 th percentile	17.86%	16.14%	18.32%	16.44%	17.54%
Median	6.57%	8.59%	9.21%	7.69%	8.60%
25 th percentile	2.70%	4.34%	5.04%	5.00%	5.29%
5 th percentile	0.00%	0.00%	0.00%	0.00%	1.39%
Min	0.00%	0.00%	0.00%	0.00%	0.00%


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
162	100.00%	125	77.16%

Comments:

The overall study rate increases by about 4 percentage points. This increase is due to centres with already high enrolment rates before, because as in the previous year, 37 centres miss the target. 11 of them were below 5% in both years. Frequent reasons were overall too few available studies and/or studies that fit the inclusion criteria, the patients' lack of willingness to participate as well as recruitment stops or delayed study start. Despite numerous efforts (some of which were already foreseeably successful) on the part of the centres, the auditors issued 4 recommendations and 1 deviation.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.

5. Total case number



	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Number	Primary cases with a genital malignoma (Def. 1.2.1)	97	68 - 722	20,964
	Target value ≥ 75			

Sollvorgabe = target value




	2015	2016	2017	2018	2019
Max	467,00	571.00	654.00	649.00	722.00
95 th percentile	243.00	253.65	262.00	255.80	250.70
75 th percentile	144.00	147.00	145.50	133.00	141.75
Median	103.00	106.50	101.00	101.00	97.00
25 th percentile	87.00	89.00	86.00	86.00	85.00
5 th percentile	78.00	76.35	75.90	76.40	77.05
Min	77.00	67.00	63.00	65.00	68.00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
162	100.00%	161	99.38%

Comments:


The total number of cases treated in the centres of the annual report increases by 8.26%. Despite a declining median, only 1 centre (previous year: 5) failed to meet the target of at least 75 cases. The centre attributed this to an expandable cooperation with referring physicians and intensified contact management and events. The auditors made one comment. Since the centre was undergoing a surveillance audit, it was possible to fall short of the target value.

6. Primary cases



	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Number	Primary cases with a genital malignoma (Def. 1.2.1)	78	48 - 413	14,986
	Target value ≥ 50			

Sollvorgabe = target value




	2015	2016	2017	2018	2019
Max	240.00	332.00	364.00	352.00	413.00
95 th percentile	173.00	172.85	164.20	184.20	172.95
75 th percentile	111.00	107.50	105.00	103.00	103.50
Median	79.00	75.50	77.00	78.00	78.00
25 th percentile	65.00	65.00	65.00	66.00	63.00
5 th percentile	55.20	52.35	52.90	52.80	52.00
Min	47.00	45.00	43.00	42.00	48.00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
162	100.00%	161	99.38%

Comments:

The total number of primary cases increased by 8.89%. Only 1 centre (previous year: 5) treated fewer than 50 primary cases (a different centre from indicator 5). As it was in the surveillance audit, the shortfall was possible. The centre explained the shortfall by the fact that some patients had to be referred to other hospitals for treatment due to surgery postponements. At the time of the audit, compliance with the 2020 target was already foreseeable.


7. Surgical cases



162 Clinical sites

Sollvorgabe = target value

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Number	Surgical cases with a genital malignoma (Def. 5.2.6)	73.5	40 - 446	14,958
	Target value ≥ 40			




	2015	2016	2017	2018	2019
Max	288.00	355.00	412.00	402.00	446.00
95 th percentile	191.60	186.55	178.10	190.80	183.55
75 th percentile	108.00	115.25	113.50	109.00	106.00
Median	81.00	80.50	77.00	77.00	73.50
25 th percentile	66.00	66.00	64.00	64.00	60.25
5 th percentile	55.00	51.00	48.90	46.40	46.05
Min	46.00	44.00	40.00	36.00	40.00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
162	100.00%	162	100.00%

Comments:

While 3 centres still failed to meet the target of at least 40 operative cases in the indicator year 2018, all centres achieved it in 2019. The total number of surgical cases rose by 6.68% compared to the previous year and thus less strongly than the total number of cases (+8.26%, cf. indicator 5). With a decreasing median, the dispersion increases, especially due to the increase in the already high case numbers of centres.


8. Offering of genetic testing (GL ovary QI 2)



Begründungspflicht = mandatory statement of reasons

113 Clinical sites

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with offer genetic testing	13*	0 - 143	1,874
Denominator	Primary cases ovary carcinoma	21*	8 - 218	2,994
Rate	No target value	61.11%	0.00% - 100%	62.59%**



	2015	2016	2017	2018	2019
● Max	----	----	----	----	100%
95 th percentile	----	----	----	----	100%
75 th percentile	----	----	----	----	82.86%
Median	----	----	----	----	61.11%
25 th percentile	----	----	----	----	38.46%
5 th percentile	----	----	----	----	7.69%
● Min	----	----	----	----	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
113	69.75%	----	----

Comments:

This QI of the guideline was collected for the first time in the 2019 indicator year and was therefore still optional. The 113 centres that provided data offered genetic testing for the initial diagnosis of ovarian carcinoma in just under 63% of cases. The spread here is very large. Since a target has not yet been set, the centres have not yet provided any justification. This will change from the audit year 2021.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.




9. Surgical staging early ovarian cancer (GL ovary QI 1)



Begründungspflicht = mandatory statement of reasons

162 Clinical sites

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Surgical primary cases with an ovarian cancer FIGO I-IIIa and surgical staging (Def. see Indicator Sheet)	5*	0 - 38	992
Denominator	Surgical primary cases with an ovarian cancer FIGO I-IIIa	6*	1 - 38	1,220
Rate	Mandatory statement of reasons*** < 20%	84.62%	0.00% - 100%	81.31%**



	2015	2016	2017	2018	2019
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	85.71%	85.71%	83.33%	86.61%	84.62%
25 th percentile	66.67%	69.69%	66.67%	69.17%	63.64%
5 th percentile	33.33%	27.92%	40.00%	34.79%	33.33%
Min	0.00%	0.00%	25.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
161	99.38%	159	98.76%

Comments:

Overall, the rate of surgical staging for ovarian cancer increased by about 1.5 percentage points. 1 centre did not treat any patients with FIGO I-IIIa. The dispersion of the values of the remaining centres remains very large. The 2 centres with justifiable low rates of 0% had 1 and 2 patients in the denominator, respectively. In 1 case, the diagnosis of ovarian carcinoma was only made postoperatively (previously: BOT). In the remaining two cases, the smallest possible intervention was chosen for very elderly patients.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.




10. Macroscopic complete resection of advanced ovarian cancer (GL ovary QI 3)



Begründungspflicht = mandatory statement of reasons

162 Clinical sites

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Surgical primary cases ovarian cancer FIGO IIB-IV with macroscopic complete resection	7,5*	1 - 128	1,698
Denominator	Surgical primary cases ovarian cancer FIGO IIB-IV	11*	1 - 171	2,360
Rate	Target value $\geq 30\%$	73.33%	25.00% - 100%	71.95%**



	2015	2016	2017	2018	2019
● Max	100%	100%	100%	100%	100%
95 th percentile	98.62%	100%	100%	100%	100%
75 th percentile	75.00%	84.16%	82.74%	84.62%	85.71%
Median	62.50%	69.66%	70.59%	70.00%	73.33%
25 th percentile	50.00%	54.49%	57.52%	56.25%	62.50%
5 th percentile	25.45%	33.33%	39.87%	38.50%	40.00%
● Min	0.00%	15.38%	19.05%	0.00%	25.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	160	98.77%

Comments:

The previous obligation to justify $>90\%$ and $<30\%$ was converted into a target (30%) for the indicator year 2019. 2 centres failed to meet the target with rates of 25% (4 and 8 patients in the denominator). The centres attributed this to a high proportion of metastatic stages and the patient's wish.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.




11. Surgery advanced ovarian cancer (GL ovary QI 4)



Begründungspflicht = mandatory statement of reasons

162 Clinical sites

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Surgical primary cases ovarian cancer FIGO IIB-IV, whose definitive surgical therapy was performed by a gynaeco-oncologist	10*	1 - 162	2,211
Denominator	Surgical primary cases ovarian cancer FIGO IIB-IV after completion of surgical therapy	11*	1 - 171	2,360
Rate	Mandatory statement of reasons*** < 50%	100%	54.55% - 100%	93.69%**



	2015	2016	2017	2018	2019
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	93.75%	100%	100%	100%	100%
25 th percentile	80.00%	81.82%	83.33%	87.50%	89.17%
5 th percentile	50.00%	66.67%	59.93%	60.00%	66.82%
Min	21.74%	40.00%	25.00%	50.00%	54.55%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	162	100.00%

Comments:

As in the previous year, all centres were above the justifiable quota of 50%. In 111 centres, all operations were performed by gynaecological oncologists. Over the years, an increasing implementation of the guideline recommendation can be seen in the certified centres.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.




12. Post-surgical chemotherapy advanced ovarian cancer (GL ovary QI 5)



Begründungspflicht = mandatory statement of reasons

162 Clinical sites

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Surgical primary cases ovarian cancer FIGO IIB-IV with post-operative chemotherapy	8*	1 - 168	1,774
Denominator	Surgical primary cases ovarian cancer FIGO IIB-IV and chemotherapy	10*	1 - 171	2,114
Rate	Mandatory statement of reasons*** < 30%	88.89%	40.91% - 100%	83.92%**



	2015	2016	2017	2018	2019
● Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	93.33%	90.91%	90.00%	94.28%	88.89%
25 th percentile	85.71%	76.74%	80.00%	80.00%	77.14%
5 th percentile	66.67%	51.17%	54.10%	55.80%	50.00%
● Min	33.33%	40.00%	33.33%	30.77%	40.91%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	162	100.00%

Comments:


None of the centres is below the limit of 30% for the obligation to give reasons. This indicator is also based on a QI of the guideline, which is thus implemented very well by the centres. Compared to the previous year, the proportion of chemotherapies performed postoperatively in patients with ovarian cancer FIGO IIB-IV and chemotherapy decreased overall and in the median. Since no centre was required to give reasons, information on the reasons for the scattering of the values is missing so far.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.


13. First-line chemotherapy of advanced ovarian cancer (GL ovary QI 8)



Begründungspflicht = mandatory statement of reasons

162 Clinical sites

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Primary cases ovarian cancer FIGO IIB-IV with 6 cycles first-line chemotherapy carboplatin AUC 5 and paclitaxel 175 mg/m2	9*	1 - 191	1,913
Denominator	Primary cases ovarian cancer FIGO IIB-IV	15*	3 - 195	3,196
Rate	Mandatory statement of reasons*** < 20%	57.14%	10.00% - 100%	59.86%**



	2015	2016	2017	2018	2019
● Max	100%	100%	100%	100%	100%
95 th percentile	93.05%	94.42%	91.09%	94.62%	92.86%
75 th percentile	81.25%	77.60%	77.78%	80.00%	71.43%
Median	62.50%	63.97%	64.71%	60.87%	57.14%
25 th percentile	47.06%	42.86%	50.00%	47.22%	42.98%
5 th percentile	22.95%	21.32%	24.85%	24.40%	23.08%
● Min	7.14%	0.00%	0.00%	0.00%	10.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	158	97.53%

Comments:
 With a slightly lower overall rate, the vast majority of centres continue to be above 20%. The 4 centres below this rate (previous year: 2) declared that they had deviated from the therapy scheme of the numerator due to comorbidities, side effects, allergies, high age and/or poor general condition. In some cases, primary chemotherapy with interval surgery was also performed.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.




14. Presentation at the tumour board (GL cervix QI 1)



Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients (primary cases and "non-primary cases") presented at the tumour conference	16*	5 - 80	3,426
Denominator	Patients with an initial diagnosis, recurrence or new remote metastasis of a cervical carcinoma	16*	5 - 83	3,511
Rate	Target value ≥ 80%	100%	72.22% - 100%	97.58%**



	2015	2016	2017	2018	2019
● Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 th percentile	94.12%	93.75%	93.33%	94.12%	95.50%
5 th percentile	82.55%	80.64%	83.82%	79.09%	88.89%
● Min	43.75%	31.58%	66.67%	56.25%	72.22%


Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	161	99.38%

Comments:

The presentation rate for cervical carcinoma has risen to almost 98%. The dispersion has further decreased and shows an increasing implementation of the guideline QI in the centres over the years. Only 1 centre failed to meet the target. This was due to 2 patients who had died before the date of the tumour board.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.


15. Details in the pathology report in the case of initial diagnosis and tumour resection (GL cervix QI 2)



Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Surgical primary cases" cervical carcinoma with complete test reports	7*	1 - 33	1,449
Denominator	Surgical primary cases with cervical carcinoma and tumour resection	7*	1 - 38	1,590
Rate	Target value ≥ 80%	100%	28.57% - 100%	91.13%**

*



	2015	2016	2017	2018	2019
● Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	85.71%	87.23%	87.50%	100%	100%
25 th percentile	57.14%	60.74%	59.73%	66.67%	84.62%
5 th percentile	1.18%	12.02%	6.98%	37.50%	71.43%
● Min	0.00%	0.00%	0.00%	0.00%	28.57%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
161	99.38%	149	92.55%


Comments:

This QI of the guideline is also being implemented increasingly better by the centres over the years. For the first time, a target was introduced in the indicator year, which 12 centres failed to meet. Most frequently, information on three-dimensional tumour size and grading was missing in the findings reports. The centres concerned sought dialogue with the pathology department. Sometimes no tumour was detectable in the preparations (e.g. after neoadjuvant pre-treatment).

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
** Percentage of the total number of patients treated in centres according to the indicator.



16. Details in the pathology report in the case of lymphonodectomy (GL cervix QI 3)




Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2018		
		Median	Range	Patients Total
Numerator	"Surgical cases" with a pathology report with details on the lymph nodes	6*	1 - 31	1,220
Denominator	"Surgical cases" with cervical carcinoma and lymphonodectomy	6*	1 - 31	1,248
Rate	Sollvorgabe ≥ 80%	100%	71.43% - 100%	97.76%**

156 Clinical sites

*



	2015	2016	2017	2018	2019
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 th percentile	77.78%	87.50%	84.62%	95.21%	100%
5 th percentile	42.00%	63.08%	50.00%	63.96%	85.71%
Min	0.00%	21.05%	0.00%	40.00%	71.43%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
156	96.30%	155	99.36%


Comments:

An 80% target was also introduced for the first time for this QI of the guideline concerning the reports on findings. Thanks to the increasing implementation over the years, only 1 centre failed to meet this target with 71.43%. Here, the information on the extent of the largest lymph node metastasis was missing for 2 patients. The centre had the specimens re-examined and organised a quality circle in order to be able to provide complete reports of the findings in the future.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.




17. Cytological/histological lymph node staging (GL cervix QI 4)



Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	"Total cases" with cytological/histological lymph node staging	6*	0 - 36	1,406
Denominator	"Total cases" with cervical carcinoma FIGO stages ≥ IA2-IVA	9*	1 - 53	1,949
Rate	Mandatory statement of reasons*** <0.01%	73.51%	0.00% - 100%	72.14%**



	2015	2016	2017	2018	2019
● Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	85.71%	88.89%	89.45%	90.91%	85.71%
Median	66.67%	75.00%	80.00%	80.00%	73.51%
25 th percentile	42.86%	54.55%	60.77%	66.67%	55.56%
5 th percentile	0.71%	17.29%	27.04%	38.50%	25.11%
● Min	0.00%	0.00%	3.85%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	158	97.53%

Comments:

The overall rate and median have decreased compared to the previous year. 4 centres (previous year: 1) had to explain a rate of 0%. The centres referred, among other things, to cases with clinically clear imaging, limiting comorbidities and rejection by the patient.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.




18. Brachytherapy as a component of primary radio(chemo) therapy



Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator in which brachytherapy was administered as part of primary radio(chemo) therapy	2*	0 - 17	332
Denominator	Primary cases with cervical carcinoma and primary radio(chemo) therapy	3*	1 - 33	454
Rate	Mandatory statement of reasons*** <math>< 75\%</math>	100%	0.00% - 100%	73.13%**



	2015	2016	2017	2018	2019
● Max	----	----	----	----	100%
95 th percentile	----	----	----	----	100%
75 th percentile	----	----	----	----	100%
Median	----	----	----	----	100%
25 th percentile	----	----	----	----	66.67%
5 th percentile	----	----	----	----	25.00%
● Min	----	----	----	----	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
94	58.02%	67	71.28%

Comments:


Of the 94 centres that treated cervical carcinomas with primary radiochemotherapy, 67 also included brachytherapy in at least ¼ of the cases. The remaining 27 centres requiring justification explained that they had not performed brachytherapy for technical reasons (anatomical conditions, localisation or extension of the tumour), in cases of old age and/or poor general condition or rejection by the patient. These explanations could be plausibilised in the audits.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.


19. Details in pathology report in the case of initial diagnosis and tumour resection (GL vulva QI 1)



162 Clinical sites

Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients with pathology reports (def. see Data Sheet)	6*	0 - 59	1,332
Denominator	Patients with initial diagnosis vulvar cancer and tumour resection	7*	1 - 60	1,414
Rate	Target value ≥80%	100%	0.00% - 100%	94.20%**



	2015	2016	2017	2018	2019
● Max	-----	100%	100%	100%	100%
95 th percentile	-----	100%	100%	100%	100%
75 th percentile	-----	100%	100%	100%	100%
Median	-----	94.26%	95.22%	100%	100%
25 th percentile	-----	79.64%	72.32%	85.71%	88.89%
5 th percentile	-----	0.00%	18.44%	42.29%	75.00%
● Min	-----	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
162	100.00%	151	93.21%


Comments:

The good development of this guideline QI means that only 11 centres (previous year: 21) had complete reports of findings in less than 80% of cases. In most cases, individual details were missing, which could sometimes be plausibilised (e.g. no pN indication for pT1a). In some cases, no tumour was detectable in the specimen (complete removal during biopsy, resection). The centre with 0% had only 1 patient in the denominator.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.




20. Details in pathology report in the case of lymphonodectomy (GL vulva QI 2)



Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients with pathology reports (def. see Data Sheet)	4*	1 - 52	854
Denominator	Patients with initial diagnosis vulvar cancer and lymphonodectomy	4*	1 - 52	863
Rate	Target value ≥80%	100%	66.67% - 100%	98.96%**



	2015	2016	2017	2018	2019
Max	-----	100%	100%	100%	100%
95 th percentile	-----	100%	100%	100%	100%
75 th percentile	-----	100%	100%	100%	100%
Median	-----	100%	100%	100%	100%
25 th percentile	-----	100%	100%	100%	100%
5 th percentile	-----	75.50%	75.33%	83.33%	98.69%
Min	-----	0.00%	0.00%	50.00%	66.67%


Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
156	96.30%	155	99.36%

Comments:

This QI of the guideline has now been implemented almost completely in the centres: 148 centres achieved 100% and only 1 centre failed to meet the target of at least 80% because of 1 out of 3 patients. In this specific case, the report on the findings did not include information on capsular rupture. This problem was addressed through consultation with the pathology department.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.


21. Conduct inguinofemoral staging (GL vulva QI 6)



161 Clinical sites

Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients with surgical staging of inguinofemoral lymph nodes	5*	0 - 40	999
Denominator	Patients with initial diagnosis vulvar cancer \geq pT1b (no basal cell carcinoma and no verrucous carcinoma)	5*	1 - 42	1,101
Rate	Target value \geq 90%	100%	0.00% - 100%	90.74%**



	2015	2016	2017	2018	2019
● Max	-----	100%	100%	100%	100%
95 th percentile	-----	100%	100%	100%	100%
75 th percentile	-----	100%	100%	100%	100%
Median	-----	88.89%	93.75%	100%	100%
25 th percentile	-----	72.92%	80.00%	80.91%	85.71%
5 th percentile	-----	50.00%	50.00%	52.14%	50.00%
● Min	-----	25.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
161	99.38%	114	70.81%


Comments:

While 95 centres performed surgical staging in all patients of the denominator, 47 failed to meet the target of at least 90% (10 fewer than in the previous year). In the vast majority of cases, this was due to elderly and/or multimorbid patients, distant metastases or the patient's refusal. This could be plausibilised in the audits. In many centres, the weight of a single case was comparatively high due to small numbers in the denominator.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.




22. Sentinel lymph nodes biopsy (GL vulva QI 7)



147 Clinical sites

Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	Patients with the presence of the described characteristics (def. see Data Sheet)	4*	0 - 48	687
Denominator	Patients with primary diagnosis of an invasive vulvar cancer and a sentinel lymph node biopsy	4*	1 - 51	739
Rate	Target value ≥ 80%	100%	0.00% - 100%	92.96%**



	2015	2016	2017	2018	2019
● Max	-----	100%	100%	100%	100%
● 95 th percentile	-----	100%	100%	100%	100%
● 75 th percentile	-----	100%	100%	100%	100%
● Median	-----	100%	100%	100%	100%
● 25 th percentile	-----	55.00%	80.00%	85.71%	100%
● 5 th percentile	-----	0.00%	8.21%	50.00%	66.67%
● Min	-----	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
147	90.74%	136	92.52%


Comments:

Over the years, the indication quality for sentinel lymph node biopsy has steadily improved. 111 centres have fulfilled the required characteristics in all cases. Only 11 centres (previous year: 18) failed to meet the target, although the reasons for this varied greatly. In most cases, individual criteria of the numerator (missing ultrastaging, tumour >4cm) were not met. Sometimes organisational problems (e.g. staff turnover) were also decisive. Here, it was possible to raise awareness of the problem, e.g. with SOP. The centre with a rate of 0% had only 1 patient in the denominator.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.




23. Systematic lymphadenectomy (LNE) for type-I-endometrial carcinoma (GL Endo QI1)



	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	No Adjuvant chemotherapy for type-I-endometrial carcinoma pT1a/b G1 cN0/pN0 o. pT1a/b G2 cN0/pN0	0*	0 - 3	28
Denominator	Primary cases of the denominator with a systematic lymphadenectomy	10*	1 - 33	1,703
Rate	Target value ≤ 5%	0.00%	0.00% - 33.33%	1.64%**

Sollvorgabe = target value



	2015	2016	2017	2018	2019
Max	-----	-----	-----	33.33%	33.33%
95 th percentile	-----	-----	-----	14.11%	9.09%
75 th percentile	-----	-----	-----	0.00%	0.00%
Median	-----	-----	-----	0.00%	0.00%
25 th percentile	-----	-----	-----	0.00%	0.00%
5 th percentile	-----	-----	-----	0.00%	0.00%
Min	-----	-----	-----	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
159	98.15%	143	89.94%


Comments:

The first mandatory documentation of this QI of the guideline shows that 136 centres did not perform LNE for type I endometrial cancer in any case. 16 centres did this in more than 5 % of cases, which was checked in the audits: In most cases, the patients also had ovarian or cervical carcinoma, which justified systematic LNE. Sometimes a G3 finding from the corpus abradate turned out to be G2 histologically.


*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators
 ** Percentage of the total number of patients treated in centres according to the indicator.



24. Adjuvant chemotherapy for type-I-endometrial carcinoma (GL Endo QI 2)



	Indicator definition	All clinical sites 2019		
		Median	Range	Patients Total
Numerator	No Adjuvant chemotherapy for type-I-endometrial carcinoma pT1a/b G1 cN0/pN0 o. pT1a/b G2 cN0/pN0	0*	0 - 2	13
Denominator	Primary cases of the denominator with adjuvant chemotherapy	13*	1 - 38	2,161
Rate	Target value ≤ 5%	0.00%	0.00% - 25.00%	0.60%**



	2015	2016	2017	2018	2019
Max	----	----	----	20.00%	25.00%
95 th percentile	----	----	----	4.76%	4.57%
75 th percentile	----	----	----	0.00%	0.00%
Median	----	----	----	0.00%	0.00%
25 th percentile	----	----	----	0.00%	0.00%
5 th percentile	----	----	----	0.00%	0.00%
Min	----	----	----	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
159	98.15%	154	96.86%

Comments:

This indicator was also collected for the first time in 2019 on a mandatory basis in all centres and was already implemented very well by them. Only 5 centres had carried out adjuvant chemotherapy in more than 5% of patients with type I endometrial carcinoma. The most frequent reason for this was a simultaneously existing ovarian carcinoma. The centre with a rate of 25% had administered chemotherapy to 1 in 4 patients due to peritoneal carcinomatosis.

*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

** Percentage of the total number of patients treated in centres according to the indicator.

*** If value is outside the plausibility corridor, centres have to give an explanation.



WISSEN AUS ERSTER HAND (FIRST-HAND KNOWLEDGE)



Find out more on www.krebsgesellschaft.de

Autoren

Deutsche Krebsgesellschaft e.V.
Deutsche Gesellschaft für Gynäkologie u. Geburtshilfe e.V.
Arbeitsgemeinschaft Gynäkologische Onkologie e.V.
Zertifizierungskommission Gynäkologische Krebszentren
Matthias W. Beckmann, Sprecher Zertifizierungskommission
Christian Dannecker, Stellv. Sprecher Zertifizierungskommission
Simone Wesselmann, Deutsche Krebsgesellschaft e.V.
Johannes Rückher, Deutsche Krebsgesellschaft e.V.
Ellen Griesshammer, Deutsche Krebsgesellschaft e.V.
Agnes Bischofberger, OnkoZert
Florina Dudu, OnkoZert
Julia Ferencz, OnkoZert

Imprint

Publisher and responsible for content:
Deutsche Krebsgesellschaft (DKG)
Kuno-Fischer-Straße 8
14057 Berlin
Tel.: +49 (030) 322 93 29 0
Fax: +49 (030) 322 93 29 66
Vereinsregister Amtsgericht Charlottenburg,
Vereinsregister-Nr.: VR 27661 B
V.i.S.d.P.: Dr. Johannes Bruns

in cooperation with:
OnkoZert, Neu-Ulm
www.onkozert.de

Version e-A1-en; 18.05.2021

ISBN: 978-3-948226-54-1

